Fast Diagnostics in Sepsis Care Could Save Lives and Cut Costs

bioMérieux, a leader in in vitro diagnostics, has unveiled a health economic analysis demonstrating that early use of rapid diagnostics in sepsis care could significantly enhance patient outcomes and reduce healthcare costs across G7 countries. Conducted by the Office of Health Economics, the study covered Canada, France, Germany, Italy, Japan, the UK, and the US.

The analysis highlights that quick identification and antimicrobial susceptibility testing (ID/AST) can prevent the deterioration of patients at risk of sepsis, potentially lowering sepsis rates by over 20%. This could result in better survival rates and reduced post-sepsis complications.

On a financial level, deploying fast diagnostics early is cost-saving across all examined nations. Savings per patient range from €500 to €3,800, primarily driven by reduced ICU admissions and shorter hospital stays. National savings differ, reaching up to €2.5 billion in the US.